patent/CO-6351788-A2

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6351788-A2

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
filingDate	2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d361c8cd448909c6953bdb08cd51e78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd53ce2c4146d033830f604a531158d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9a7fd2923c9bdbac3f262bd97957c0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_209259f9f93ce12923b6dae8f91c4a70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7349ea829414967d1686f0aeaeb81a28
publicationDate	2011-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CO-6351788-A2
titleOfInvention	DERIVATIVES OF ISOXAZOLO PIRIDINA
abstract	The present invention relates to isoxazol-pyridine derivatives of the formula I in which X, from R1 to R6 have the meanings defined in claim 1. These compounds are active at the GABA A a5 receptor binding site and are useful for the treatment of cognitive disorders, for example Alzheimer's disease.
priorityDate	2007-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1049 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452923700 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547992 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66619066 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487869

Total number of triples: 35.